Five ways to invest in living longer, and the one small-cap we think retail investors should research first.
A market chart, or a pulse that keeps going. This report is about the companies betting on the second one.
Meet Dana. She isn't a real person. She's a composite of the patients doctors describe, and you have almost certainly met someone like her.
Dana is 54. Two years ago she started a GLP-1 weight-loss drug. She lost 50 pounds. Her blood pressure came down. Her jeans got loose. Everyone told her she looked great.
Then she looked in the mirror. Her cheeks had hollowed. Her skin looked loose. Her face looked older than it did before she got healthy.
Dana is not unusual. In July 2026, Gallup found that 11% of U.S. adults were currently taking a GLP-1 drug for weight loss, up from 3% just two years earlier. Fifteen percent had taken one at some point.1 That's about one adult in nine. A systematic review in Aesthetic Surgery Journal Open Forum documents facial volume loss and skin changes after major GLP-1 weight loss.2 People call it "Ozempic Face."
Now here's the part an investor should notice. When Eli Lilly's GLP-1 franchise took off, Lilly became the first healthcare company ever to reach a $1 trillion market value. It added nearly $700 billion in value between the end of 2022 and November 2025.3 Wall Street priced the drug.
Almost nobody has priced Dana.
Here's why that matters. McKinsey surveyed 174 U.S. providers in 2025 and found that 63% of GLP-1 patients seeking facial aesthetic treatment had no prior aesthetic history.4 These aren't customers switching providers. They are brand-new customers, created by a drug.
That's one thread. Pull it and you find a much bigger story. Americans over 50 generated an estimated $12.5 trillion in economic activity in 2024, which AARP says is 43% of U.S. GDP and enough to rank as the world's third-largest economy. That figure is projected to nearly double to $24 trillion by 2060.5 Everything that helps bodies work longer has a very large customer waiting.
This report walks through five doors into that market. We start where the money has already been made: the drugs that created Dana's problem. We end at the mirror, with the company we think is trying to solve it. In between you'll meet a software company that sells shovels, a biotech valued close to the cash in its bank account, and a lottery ticket with a lawyer attached.
We'll tell you what could go wrong with every name, including our favorite.
Especially our favorite.
Our favorite is Conexeu Sciences (Nasdaq: CNXU). It's also the riskiest stock in this report. Its own latest filing says there is "substantial doubt" it can continue as a going concern.6 We still think it's the most interesting door, and we'll show you why. We'll also tell you what remains unproven. Read both.
economic activity by U.S. adults 50+ in 2024, headed to $24T by 20605
U.S. health care spending by adults 50+ in 2024, projected to more than double by 20605
of U.S. adults currently taking a GLP-1 drug, up from 3% in two years1
of GLP-1 patients seeking facial aesthetics were new to the category4
Think about what those numbers mean together. A huge, wealthy, aging population. A class of drugs that is changing how tens of millions of those people look. And a medical system that was built to treat disease, not to rebuild what rapid weight loss leaves behind.
| Market | Today | Projected | Source |
|---|---|---|---|
| U.S. economic activity, adults 50+ (2024) | $12.5T | $24T by 2060 | AARP5 |
| Weight-loss drug market (2024) | about $15B | about $150B within 10 years | Morgan Stanley est., via Nasdaq7 |
| Aesthetic injectables (2024) | $12.18B | $24.13B by 2030 | Grand View Research8 |
| Post-GLP-1 aesthetic restoration | about $0.7B | about $2B within five years | BCG9 |
| Wound care devices | $2.6B (2023) | $4.2B by 2033 | Market.us10 |
Different research firms size markets differently, and projections are estimates, not promises. Use these for scale, not precision.
Lilly's two tirzepatide drugs, Mounjaro and Zepbound, did about $16.5 billion in combined sales in 2024.11 That one pair of drugs helped push a company past a trillion dollars. The market for fixing what those drugs do to the face and body is about $0.7 billion today.9 If the drug market really grows tenfold, how big does the aftermath get? Nobody knows. That is exactly the point.
We ordered the doors by distance from Dana. Door One is the drug that caused the problem. Door Five is the mirror she's staring into. The further down the list, the smaller the company and the bigger the risk.
| Door | The bet in one line | Next dated catalyst | Biggest risk |
|---|---|---|---|
| 1. The Challenger Viking (VKTX) | A better GLP-1 pill and injection | Oral Phase 3 starts, Q4 2026 | Priced for perfection after a $548M raise |
| 2. The Shovel Seller Schrödinger (SDGR) | Sells drug-discovery software to pharma | Bunsen full release, late 2026 | Software revenue fell 10% in Q2 during a billing switch |
| 3. The Clock BioAge (BIOA) | Aging-biology drugs, valued near cash | Phase 2 heart data, H2 2026 | Novo's ZEUS failure hit the heart thesis |
| 4. The Courier Capricor (CAPR) | Exosome platform riding an FDA decision | FDA decision, Nov. 22, 2026 | Class action and a negative FDA panel vote |
| 5. The Mirror Conexeu (CNXU) | A tissue-structure scaffold for the post-GLP-1 body | 510(k) filing, targeted by Mar. 31, 2027 | Going-concern doubt; about $2.0M cash at July 31, before a ~$5M private placement in October57 |
Each company gets the same four questions, in the same order, so you can compare them with each other and with anything already in your portfolio.
One more rule. When you see "our math" or "for illustration," that's arithmetic we did to give you a sense of scale. It is not a forecast and not a promise.
If Eli Lilly and Novo Nordisk are Coke and Pepsi, Viking Therapeutics is the upstart with a formula it says tastes better and lasts longer. And it's trying to get on the shelf next to them.
The shelf is worth fighting for. The weight-loss drug market did roughly $15 billion in 2024. Morgan Stanley thinks it could reach $150 billion.7 Lilly's tirzepatide drugs alone did about $16.5 billion in 2024.11 Viking has no product yet. It has a peptide called VK2735 and some numbers that got Wall Street's attention.
If a next-generation GLP-1 can keep weight off with less frequent dosing, and a pill version works, Viking wins a slice of a market that could be ten times bigger than today.
Start of the oral VK2735 Phase 3 trial, expected in Q4 2026.13
In every gold rush, the surest money tends to go to the people selling picks and shovels. In drug discovery, the shovel is software that predicts which molecules are worth building. Schrödinger sells it.
Why does that belong in a longevity report? Because every other door in this report starts with a molecule. Faster, cheaper discovery helps all of them. Schrödinger gets paid when pharma uses its tools, whether or not any single drug works.
AI makes every drug team faster. Schrödinger collects a toll on the road, and a few lottery tickets from its own drug programs.
Bunsen's full release, which one analyst called critical, expected in late 2026.20
Most drug companies chase one disease at a time. BioAge Labs starts from a different idea: if you can target the biology of aging itself, one drug might help several age-related conditions.
On July 31, 2026, Novo Nordisk's heart-inflammation drug failed a major trial. BioAge's stock fell more than 60%, and Citi said the company's enterprise value, its market value minus the cash it holds, was nearing zero.22 In plain English: for a moment, the market was valuing everything BioAge owns except its cash at about nothing.
The market has marked down BioAge's heart-disease dream. You're betting the eye-disease program, the Novartis deal and a big cash cushion are worth more than the market thinks.
QUELL-CV Phase 2 topline, expected in H2 2026.28
Your cells constantly mail tiny packages, called exosomes, to each other. Scientists hope to load those packages with medicine. It's a delivery system for the body, and it's wide open: the FDA's own safety notification says there are currently no FDA-approved exosome products.30
Capricor has an exosome platform called StealthX. In 2025 the FDA cleared its first test, a government-funded vaccine study.31 But the stock doesn't trade on StealthX. It trades on a different product, a cell therapy called deramiocel, and an FDA decision due November 22. Think of it as a lottery ticket with a lawyer attached.
If the FDA approves deramiocel, Capricor becomes a commercial company with money to push StealthX forward. If it doesn't, the stock has already shown what can happen.
FDA decision on deramiocel, due November 22, 2026.32
Dana's problem doesn't have a good fix yet. That's the opportunity. One small company thinks it has the missing piece: Conexeu Sciences (Nasdaq: CNXU). It is developing an injectable liquid called Ten-Minute Tissue™, designed to give the body's own cells a scaffold to rebuild tissue.38 It is still preclinical, and we'll be straight with you about what that means.
About 90% of dermal filler is hyaluronic acid.39 It works by swelling with water and typically lasts 6 to 12 months.40 That's fine for a wrinkle. It isn't built to rebuild the structure a face loses when 50 pounds disappear.
Every fortune in aesthetics has been built on a different mechanism. Botox works on muscle. Fillers work on volume. Biostimulators (like Sculptra and Radiesse) work by stimulation, prompting a mild inflammatory response that leads the body to make collagen. Three mechanisms. Three multibillion-dollar categories.
The fourth mechanism is structure: giving the body's own cells something to build on.
We are not saying Conexeu is Botox. Most new categories fail.
Picture a clear liquid in a syringe. Inject it, and in about ten minutes at body temperature it sets into a soft scaffold that resembles the body's own structural mesh, called the extracellular matrix.[*1][*7] According to the company, it is designed so the body's own cells can move in and support tissue restoration rather than scar.38[*3][*9][*10]
The science comes out of more than a decade of work at a leading Canadian university, originally to help burn patients heal.38 Conexeu says its patents are granted in the U.S., EU, Japan and Australia and that it owns the technology outright, with no royalties owed.38
Here's the honest label: it is preclinical and investigational. It has not been tested in humans.38
| Market | Size | Projected | Source |
|---|---|---|---|
| Aesthetic injectables | $12.18B (2024) | $24.13B by 2030 | Grand View Research8 |
| Wound care devices | $2.6B (2023) | $4.2B by 2033 | Market.us10 |
| Dental soft-tissue regeneration | $1.88B (2025) | $3.13B by 2035 | Precedence Research53 |
| Veterinary wound care | about $1.6B (2025) | $2.6B by 2032 | VPA Research54 |
| 3D bioprinting | $1.6B (2023) | $6.5B by 2032 | Global Market Insights55 |
Like any early-stage device company, Conexeu has milestones still ahead. Ten-Minute Tissue™ has not yet been studied in people. The research above is preclinical, and none of the cited studies looked at the specific wound types the company plans to pursue first.38 The next step is a 510(k) submission. The FDA may ask for additional data or testing, and it will decide whether the device is substantially equivalent to its identified predicate.38 Reimbursement is worth understanding, too. Medicare now pays a flat rate per square centimeter for skin substitutes, so Conexeu will need to show its product fits within that framework.56
Competition is part of the picture. Established players such as Solventum, Integra and Smith & Nephew have sales forces, hospital contracts and clinical data that a young company is still building. The 0-of-43 format analysis is the company's own review of public FDA records and has not been independently verified.44
The milestone to watch is the 510(k) submission targeted for the first quarter of 2027, and any FDA questions that follow.6
Conexeu is trying to create the fourth mechanism in aesthetics, structure, at the exact moment tens of millions of people need it. If the FDA clears the device, a small company is aimed at billion-dollar markets. A wound-care clearance would not cover aesthetic use; aesthetics would need its own development and FDA authorization (the company has indicated a PMA pathway, estimated after 2030).44 If it doesn't, the thesis stalls.
510(k) submission targeted by March 31, 2027.6
Stories are cheap. Dates are not. Here are the next dated events across all five doors. Put them in your calendar.
| When | Who | What | Why it matters |
|---|---|---|---|
| Nov. 22, 2026 | Capricor | FDA decision on deramiocel | Binary event; the stock has already swung wildly32,34 |
| Q4 2026 | Viking | Oral VK2735 Phase 3 begins | Tests whether a pill can match the injection13 |
| H2 2026 | BioAge | QUELL-CV Phase 2 topline | Heart thesis after Novo's miss28 |
| Late 2026 | Schrödinger | Bunsen full release | Product cycle behind the growth story20 |
| By Mar. 31, 2027 | Conexeu | 510(k) submission | The gate to everything else; target already slipped once6 |
| Mid-2027 | BioAge | DME (eye disease) data | The program Citi still values24,28 |
Dates are company guidance or filings as of early October 2026 and can change.
Remember Dana?
She's still standing in front of that mirror. The drug that helped her is a trillion-dollar story. The company that makes it is one of the most valuable on earth.3 The fix for what it did to her face is, today, a $700 million question mark.9
That's the spine of this entire report. Wall Street priced the cause. We walked through the doors that lead from the cause to the cure.
Four of these doors are bets on science that still has to work. One is a bet on a problem that already exists, in a customer base that already exists, and that people are already paying to address with products that weren't built for it.
That is why Conexeu is our favorite. It is also why you should be careful. It is tiny. It has no revenue. Its own filing says there is substantial doubt it can keep operating without new money. It raised about $5 million in October and may need to raise again before it files with the FDA.57 In our opinion, a company with this much unmet need, this experienced a team, and this little left in the bank is a high-risk, high-uncertainty bet.
What would we do with this report? We'd put CNXU on a research list. We'd read the going-concern note in the 10-Q first.6 We'd watch the next financing, because its price and size will matter more than any headline. And we'd watch the 510(k) date like a hawk.
The longevity boom is real. Whether it makes you money depends on which doors you walk through, how much you carry in with you, and whether you read the fine print. Dana can't wait for the science to catch up. The question for you is whether you want to be early, and whether you can afford to be wrong.
Longevity Trader will email you as each Conexeu catalyst date approaches. Add your mobile number for text alerts too.
Get the free CNXU alertsLongevity Trader is not a securities dealer or broker, investment adviser or financial adviser, and you should not rely on the information in this report as investment advice. Conexeu Sciences Inc. has paid Longevity Trader 30,000 common shares in consideration for marketing services to be provided over a term of six months commencing June 1, 2026 and ending November 30, 2026. As of the date of this report, Longevity Trader owns 30,000 common shares of Conexeu Sciences Inc. We may sell these shares in the future, which creates a conflict of interest. Longevity Trader has received no compensation from, and holds no securities of, any other company named in this report.
This report is for informational and educational purposes only. It does not constitute an offer to sell or a solicitation of an offer to buy any security, and it is not investment, legal or tax advice. It was not prepared with regard to your objectives, finances or needs. Consult a qualified, licensed financial adviser before making any investment decision.
Every company in this report is an early-stage or small-capitalization company. The securities of the companies we profile should be considered high risk. If you invest despite these warnings, you may lose your entire investment. Conexeu Sciences Inc. is a pre-revenue company whose latest quarterly report states substantial doubt about its ability to continue as a going concern. Please do your own research, including reading each company's SEC filings, press releases and risk disclosures.
Phrases such as "we think," "our favorite" and "in our opinion" are the publisher's opinions. They are not statements of fact and not guarantees of any outcome. Statements about a company's technology, data, plans and prospects reflect that company's own disclosures or third-party reporting and have not been independently verified by the publisher.
Prices, market values and financial figures are as of early October 2026 (some Viking, BioAge and Capricor figures are earlier, as dated in the text) and come from the third-party sources numbered in this report, including aggregator websites that may be delayed or contain errors. They change daily. Passages marked "our math," "for illustration" or "for scale" are the publisher's arithmetic, not forecasts. Market-research projections are estimates and vary widely by methodology. "Dana" is a hypothetical composite, not a real person or patient.
Capricor Therapeutics is the subject of a securities class action. The allegations described in this report come from law-firm notices of the complaint; they are allegations only, are unproven, and the company may dispute them. Review the company's SEC filings for current status.
This report includes statements that may be deemed forward-looking, including statements about regulatory timelines, clinical development, market sizes and business outlooks, including Conexeu Sciences Inc.'s anticipated PMA regulatory pathway and estimated market entry after 2030 for its aesthetics indication, often identified by words such as "expects," "plans," "anticipates," "believes," "targets," "estimates," "potential," "could" and "may." Such statements are subject to known and unknown risks and uncertainties that could cause actual results to differ materially. No assurance can be given that any will prove accurate.
Conexeu Sciences Inc.'s CXU™ platform, including Ten Minute Tissue™, is investigational. Statements regarding its mechanism, performance, or potential are based on preclinical, animal-model findings; clinical significance has not yet been established, and the device has not been submitted to or cleared/approved by the FDA for any use, in any indication. A wound-care clearance, if obtained, would not cover aesthetic use. There can be no assurance that the Company will obtain regulatory clearance or approval for any indication on any timeline, or at all.
CXU™, B.R.E.A.S.T.™ and Ten Minute Tissue™ are trademarks of Conexeu Sciences Inc. Ozempic® is a registered trademark of Novo Nordisk A/S. BOTOX® is a registered trademark of Allergan, Inc., an AbbVie company. Mounjaro® and Zepbound® are registered trademarks of Eli Lilly and Company. Sculptra® and Restylane® are registered trademarks of Galderma. Radiesse® is a registered trademark of Merz North America, Inc. Bellafill® is a registered trademark of Suneva Medical, Inc. All other marks are the property of their respective owners, which are not affiliated with and have not endorsed Conexeu Sciences Inc. or this report.
Numbers in the text match the numbered sources below. Where a source has no public URL, the report is subscription or company material. Figures sourced to third-party aggregator pages may be delayed.
We'll email you as each Conexeu catalyst date approaches. Add your mobile number to get text alerts too.